EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs
Publishing timestamp: 2023-07-11 17:13:00
Summary
The European Union's drug regulator, the European Medicines Agency (EMA), has expanded its investigation into the risk of suicidal thoughts and self-injury among patients taking Novo Nordisk's weight loss and diabetes medications, including Ozempic, Wegovy, and Saxenda. The EMA is also evaluating other weight loss and diabetes drugs, including Eli Lilly's Mounjaro. The investigation comes after reports of possible cases of self-injury and suicidal thoughts in patients taking these medications. The EMA expects to complete its probe in November. Novo Nordisk has stated that safety data from clinical trials and post-marketing surveillance have not shown a causal association between their drugs and suicidal thoughts. The investigation could potentially uncover new side effects associated with these drugs.
Sentiment: NEUTRAL
Tickers: PFE, NOVO.B-DK, AMGN, LLY,
Keywords: obesity, amgen inc, breaking news, eu, weight management, health care industry, pharmaceuticals, pfizer inc, biotechnology, eli lilly and co, biotech and pharmaceuticals, suicides, novo nordisk a/s, science, mental health, business, business news, diabetes,
Source: https://www.cnbc.com/2023/07/11/weight-loss-drugs-eu-expands-ozempic-probe-over-suicide-risks.html